In this work we report a first-time combination of porous silicon (pSi) particles with the immunologic adjuvant Pam3CSK4, a TLR 1/2 agonist, as a tool for immunotherapy. pSi is a sponge-like biocompatible and biode gradable nanomaterial with high porosity, large surface-to-volume ratio and tunable surface, suitable for drug delivery applications. This study provides, by means of live-cell confocal microscopy, an insight about the time course of the interaction of free Pam3CSK4 vs vectorized by pSi microparticles with human dendritic cells (DCs). We found a delay in the ingestion of the agonist when carried by pSi microparticles. These findings were sup ported by the observation of the morphological changes related to the activation of DCs that occurred with a 5 h difference when treated with the vectorized ligand. These results provide the first demonstration of pSi as a conceivable candidate to deliver Pam3CSK4 to DCs paving the way towards immunotherapy practice.

Porous silicon microparticles as efficient carriers for immunologic adjuvants

Sambugaro, Alessia
;
Donini, Marta;Chistè, Elena;Dusi, Stefano;Daldosso, Nicola
2024-01-01

Abstract

In this work we report a first-time combination of porous silicon (pSi) particles with the immunologic adjuvant Pam3CSK4, a TLR 1/2 agonist, as a tool for immunotherapy. pSi is a sponge-like biocompatible and biode gradable nanomaterial with high porosity, large surface-to-volume ratio and tunable surface, suitable for drug delivery applications. This study provides, by means of live-cell confocal microscopy, an insight about the time course of the interaction of free Pam3CSK4 vs vectorized by pSi microparticles with human dendritic cells (DCs). We found a delay in the ingestion of the agonist when carried by pSi microparticles. These findings were sup ported by the observation of the morphological changes related to the activation of DCs that occurred with a 5 h difference when treated with the vectorized ligand. These results provide the first demonstration of pSi as a conceivable candidate to deliver Pam3CSK4 to DCs paving the way towards immunotherapy practice.
2024
Porous silicon; Pam3CSK4; Dendritic cells; Immunotherapy; Drug delivery
File in questo prodotto:
File Dimensione Formato  
Sambugaro et al. JDDST 92 (2024) 105301.pdf

accesso aperto

Licenza: Non specificato
Dimensione 8.72 MB
Formato Adobe PDF
8.72 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1116986
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact